{"id":933972,"date":"2026-02-04T08:59:29","date_gmt":"2026-02-04T13:59:29","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-therapeutics-to-participate-in-a-fireside-chat-at-guggenheims-emerging-outlook-biotech-summit\/"},"modified":"2026-02-04T08:59:29","modified_gmt":"2026-02-04T13:59:29","slug":"unicycive-therapeutics-to-participate-in-a-fireside-chat-at-guggenheims-emerging-outlook-biotech-summit","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-therapeutics-to-participate-in-a-fireside-chat-at-guggenheims-emerging-outlook-biotech-summit\/","title":{"rendered":"Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim\u2019s Emerging Outlook: Biotech Summit"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">LOS ALTOS, Calif., Feb.  04, 2026  (GLOBE NEWSWIRE) &#8212; Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the \u201cCompany\u201d or \u201cUnicycive\u201d), today announced that Shalabh Gupta, M.D., Chief Executive Officer, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit on Wednesday, February 11, 2026, at 1:30 p.m. ET.<\/p>\n<p align=\"justify\">A link to the live and archived webcast may be accessed on the Unicycive website under the Investors section: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GtO71CQm7LLkRQRHrD4lXJ6irhhrXzkzhcCU2828rNfJDSZSFkwcEJ4kR68V9jx-ACsio1IXCbGKmFG9LCkhSq7hzX3OYZCP8-TR74_EiRXWDYpWg98MKvzDX8_FO4Sluj0tXP6NZzg3OrCo38K93w==\" rel=\"nofollow\" target=\"_blank\">Events and Presentations<\/a>. To schedule a 1&#215;1 meeting with management, please contact your Guggenheim conference representative.<\/p>\n<p align=\"justify\">\n        <strong>About\u00a0Unicycive Therapeutics<\/strong>\n      <\/p>\n<p align=\"justify\">Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive\u2019s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive\u2019s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=tqclufLm14U-K6VQgYgWSvrW4JX7tGtXHNAavQHpO23VgrClKdOktsf7fCW5ArVloCO5VHqpOY4hp_PB4xJxXF_G1g6ciQOjp94_6qW_hlv1YZorq7z_SjLxHuzKIM5HjfFvkWyLVuXUisBI2QEEgZpwPc6zJbrsPBdRp4cuOYpfZjpEoct2Wk1QBRDkGtyHKBvHO3GZS0fhQLl50n6RZqRnSiljHYwsqorQwWhgmo4=\" rel=\"nofollow\" target=\"_blank\">Unicycive.com<\/a>\u00a0and follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QbNkGx56LQ_RCw6cpUmNLXrrF-_obtkSBr3pKthjDFqV8sGICfFO9k_W4NtTFrY5hzJyTMkygzi1DPCjmj7RbqS3WpJyp3IY4knppb-QzAaKoLonbhEDUEQsTkXDWtvzVkX0GAeUj-EVYdGHD0OgUtiRO8mI0Z4FueNeM8IYHvA6p653pvlls35pLeqf9orqN9z7_RNQBRE1qMHtKoXVeT042_B3CLM5CfptbT0PVFFsxq3MCIz0Ozzg1Vzz0WI_\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>\u00a0and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=r9Qq1QdmhqrthnA0DH1xnRpEDX9UZNEIHTlAmyLV8Uqn3g7bMIZNycnW3ZzhgsnpMGjNwjMOKQmjJH9IO_HSpD3Sh4JqChb2VtxJGO_bqDpuEKJX8Bv4PFtpuCleqWUSigzgsq0nufSAAjbzuifkByhOaPxG5GAW_Csj0abvrLffKkbBHRcR6FkiPyhCyBwdtYRS-1ExT8BgsGh8t4Khgg==\" rel=\"nofollow\" target=\"_blank\">X<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Investor Contact:<\/strong>\n      <\/p>\n<p>\n        <strong>Kevin Gardner<\/strong><br \/>\n        <br \/>LifeSci Advisors<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kAc1Y907V8oprdYoPwdtCtFkgffVWfqq7MHgl3GeUGScKHXdAbLODCWLU7_BzB95fHvSaEitHAYNN9p6jEtuB7Xgh0sXe0kmshKGcWfoOjnhycQDwSeUwsjpwr7q_gRAei3e1Vrl_Z2bFL-pkkhyM8LbvNhBMu36jyg80Z5p3SOxVDEwsUTNwz202-Lc13_7BvsEArMoI7LS9UIX0GmSOm114648NdJm-bO8it2rXTEGlpw1zTVwBqlw2jNQNorPhgUKHoyT5lkJ3_0Kwq3e1Ua9g7CFbeksKQonvK44dX27mR990NtVNEqHHVLui91X\" rel=\"nofollow\" target=\"_blank\">kgardner@lifesciadvisors.com<\/a><\/p>\n<p>\n        <strong>Media Contact:<\/strong>\n      <\/p>\n<p>\n        <strong>Layne Litsinger<\/strong><br \/>\n        <br \/>Real Chemistry<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3UN1pGW9I70tRRCfVvO9z2QMslv3-hsk7o7e0GnG_j-FBN7g9hBvCs_rpVYH6DIsgBha2oV02nBhWgszeus8JdDUsf7WVemvZR988Jdl_w3e313v1LTtJdKCNy3aXL8_\" rel=\"nofollow\" target=\"_blank\">llitsinger@realchemistry.com<\/a><\/p>\n<p align=\"justify\">SOURCE: Unicycive Therapeutics, Inc.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0ODI1OSM3NDA3MzQyIzIyMTA3NjM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MmYwMzc5MDItOTQzOC00ZTNiLWFmMzQtMzE4OTQ5ZWYxYzIzLTEyMjIzMTYtMjAyNi0wMi0wNC1lbg==\/tiny\/Unicycive-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>LOS ALTOS, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) &#8212; Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the \u201cCompany\u201d or \u201cUnicycive\u201d), today announced that Shalabh Gupta, M.D., Chief Executive Officer, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit on Wednesday, February 11, 2026, at 1:30 p.m. ET. A link to the live and archived webcast may be accessed on the Unicycive website under the Investors section: Events and Presentations. To schedule a 1&#215;1 meeting with management, please contact your Guggenheim conference representative. About\u00a0Unicycive Therapeutics Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive\u2019s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-therapeutics-to-participate-in-a-fireside-chat-at-guggenheims-emerging-outlook-biotech-summit\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim\u2019s Emerging Outlook: Biotech Summit&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-933972","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim\u2019s Emerging Outlook: Biotech Summit - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-therapeutics-to-participate-in-a-fireside-chat-at-guggenheims-emerging-outlook-biotech-summit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim\u2019s Emerging Outlook: Biotech Summit - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"LOS ALTOS, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) &#8212; Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the \u201cCompany\u201d or \u201cUnicycive\u201d), today announced that Shalabh Gupta, M.D., Chief Executive Officer, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit on Wednesday, February 11, 2026, at 1:30 p.m. ET. A link to the live and archived webcast may be accessed on the Unicycive website under the Investors section: Events and Presentations. To schedule a 1&#215;1 meeting with management, please contact your Guggenheim conference representative. About\u00a0Unicycive Therapeutics Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive\u2019s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding &hellip; Continue reading &quot;Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim\u2019s Emerging Outlook: Biotech Summit&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-therapeutics-to-participate-in-a-fireside-chat-at-guggenheims-emerging-outlook-biotech-summit\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-04T13:59:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0ODI1OSM3NDA3MzQyIzIyMTA3NjM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/unicycive-therapeutics-to-participate-in-a-fireside-chat-at-guggenheims-emerging-outlook-biotech-summit\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/unicycive-therapeutics-to-participate-in-a-fireside-chat-at-guggenheims-emerging-outlook-biotech-summit\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim\u2019s Emerging Outlook: Biotech Summit\",\"datePublished\":\"2026-02-04T13:59:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/unicycive-therapeutics-to-participate-in-a-fireside-chat-at-guggenheims-emerging-outlook-biotech-summit\\\/\"},\"wordCount\":250,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/unicycive-therapeutics-to-participate-in-a-fireside-chat-at-guggenheims-emerging-outlook-biotech-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY0ODI1OSM3NDA3MzQyIzIyMTA3NjM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/unicycive-therapeutics-to-participate-in-a-fireside-chat-at-guggenheims-emerging-outlook-biotech-summit\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/unicycive-therapeutics-to-participate-in-a-fireside-chat-at-guggenheims-emerging-outlook-biotech-summit\\\/\",\"name\":\"Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim\u2019s Emerging Outlook: Biotech Summit - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/unicycive-therapeutics-to-participate-in-a-fireside-chat-at-guggenheims-emerging-outlook-biotech-summit\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/unicycive-therapeutics-to-participate-in-a-fireside-chat-at-guggenheims-emerging-outlook-biotech-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY0ODI1OSM3NDA3MzQyIzIyMTA3NjM=\",\"datePublished\":\"2026-02-04T13:59:29+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/unicycive-therapeutics-to-participate-in-a-fireside-chat-at-guggenheims-emerging-outlook-biotech-summit\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/unicycive-therapeutics-to-participate-in-a-fireside-chat-at-guggenheims-emerging-outlook-biotech-summit\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/unicycive-therapeutics-to-participate-in-a-fireside-chat-at-guggenheims-emerging-outlook-biotech-summit\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY0ODI1OSM3NDA3MzQyIzIyMTA3NjM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY0ODI1OSM3NDA3MzQyIzIyMTA3NjM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/unicycive-therapeutics-to-participate-in-a-fireside-chat-at-guggenheims-emerging-outlook-biotech-summit\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim\u2019s Emerging Outlook: Biotech Summit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim\u2019s Emerging Outlook: Biotech Summit - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-therapeutics-to-participate-in-a-fireside-chat-at-guggenheims-emerging-outlook-biotech-summit\/","og_locale":"en_US","og_type":"article","og_title":"Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim\u2019s Emerging Outlook: Biotech Summit - Market Newsdesk","og_description":"LOS ALTOS, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) &#8212; Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the \u201cCompany\u201d or \u201cUnicycive\u201d), today announced that Shalabh Gupta, M.D., Chief Executive Officer, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit on Wednesday, February 11, 2026, at 1:30 p.m. ET. A link to the live and archived webcast may be accessed on the Unicycive website under the Investors section: Events and Presentations. To schedule a 1&#215;1 meeting with management, please contact your Guggenheim conference representative. About\u00a0Unicycive Therapeutics Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive\u2019s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding &hellip; Continue reading \"Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim\u2019s Emerging Outlook: Biotech Summit\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-therapeutics-to-participate-in-a-fireside-chat-at-guggenheims-emerging-outlook-biotech-summit\/","og_site_name":"Market Newsdesk","article_published_time":"2026-02-04T13:59:29+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0ODI1OSM3NDA3MzQyIzIyMTA3NjM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-therapeutics-to-participate-in-a-fireside-chat-at-guggenheims-emerging-outlook-biotech-summit\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-therapeutics-to-participate-in-a-fireside-chat-at-guggenheims-emerging-outlook-biotech-summit\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim\u2019s Emerging Outlook: Biotech Summit","datePublished":"2026-02-04T13:59:29+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-therapeutics-to-participate-in-a-fireside-chat-at-guggenheims-emerging-outlook-biotech-summit\/"},"wordCount":250,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-therapeutics-to-participate-in-a-fireside-chat-at-guggenheims-emerging-outlook-biotech-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0ODI1OSM3NDA3MzQyIzIyMTA3NjM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-therapeutics-to-participate-in-a-fireside-chat-at-guggenheims-emerging-outlook-biotech-summit\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-therapeutics-to-participate-in-a-fireside-chat-at-guggenheims-emerging-outlook-biotech-summit\/","name":"Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim\u2019s Emerging Outlook: Biotech Summit - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-therapeutics-to-participate-in-a-fireside-chat-at-guggenheims-emerging-outlook-biotech-summit\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-therapeutics-to-participate-in-a-fireside-chat-at-guggenheims-emerging-outlook-biotech-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0ODI1OSM3NDA3MzQyIzIyMTA3NjM=","datePublished":"2026-02-04T13:59:29+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-therapeutics-to-participate-in-a-fireside-chat-at-guggenheims-emerging-outlook-biotech-summit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-therapeutics-to-participate-in-a-fireside-chat-at-guggenheims-emerging-outlook-biotech-summit\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-therapeutics-to-participate-in-a-fireside-chat-at-guggenheims-emerging-outlook-biotech-summit\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0ODI1OSM3NDA3MzQyIzIyMTA3NjM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0ODI1OSM3NDA3MzQyIzIyMTA3NjM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-therapeutics-to-participate-in-a-fireside-chat-at-guggenheims-emerging-outlook-biotech-summit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim\u2019s Emerging Outlook: Biotech Summit"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/933972","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=933972"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/933972\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=933972"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=933972"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=933972"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}